DeCode Shares Surge 40 Percent on Skin Cancer SNP Findings | GenomeWeb
NEW YORK (GenomeWeb News) – Shares of DeCode Genetics climbed more than 40 percent today following an announcement that the company had discovered two SNPs associated with the risk of basal cell carcinoma, the most common cancer among people of European ancestry.
 
The boost in DeCode’s shares, which opened at $.36 today and were priced at $.54 in mid-afternoon trading, outpaced a broad rally in the capital markets following a massive sell-off in recent weeks.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.